ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 177 filers reported holding ALLOGENE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 4.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $6 | -50.0% | 2,766 | 0.0% | 0.00% | – |
Q1 2024 | $12 | -47.8% | 2,766 | -61.4% | 0.00% | – |
Q4 2023 | $23 | -8.0% | 7,163 | -10.3% | 0.00% | – |
Q3 2023 | $25 | -37.5% | 7,986 | 0.0% | 0.00% | – |
Q2 2023 | $40 | -2.4% | 7,986 | -3.2% | 0.00% | – |
Q1 2023 | $41 | -35.9% | 8,246 | -19.1% | 0.00% | -100.0% |
Q4 2022 | $64 | -99.9% | 10,192 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $110,000 | -4.3% | 10,192 | +1.0% | 0.00% | 0.0% |
Q2 2022 | $115,000 | +35.3% | 10,093 | +7.9% | 0.00% | 0.0% |
Q1 2022 | $85,000 | -71.7% | 9,350 | -53.6% | 0.00% | 0.0% |
Q4 2021 | $300,000 | +14.5% | 20,172 | +98.1% | 0.00% | -50.0% |
Q3 2021 | $262,000 | -7.7% | 10,184 | -6.4% | 0.00% | 0.0% |
Q2 2021 | $284,000 | +4.8% | 10,875 | +41.7% | 0.00% | -80.0% |
Q1 2021 | $271,000 | +27.2% | 7,676 | -8.9% | 0.01% | +25.0% |
Q4 2020 | $213,000 | -32.6% | 8,426 | +0.5% | 0.01% | -42.9% |
Q3 2020 | $316,000 | -4.8% | 8,380 | +8.0% | 0.01% | -6.7% |
Q2 2020 | $332,000 | – | 7,762 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vida Ventures Advisors, LLC | 1,798,163 | $26,829,000 | 10.04% |
Wildcat Capital Management, LLC | 1,716,370 | $25,608,000 | 4.17% |
TPG GP A, LLC | 18,716,306 | $279,247,000 | 2.79% |
Casdin Capital, LLC | 2,650,000 | $39,538,000 | 1.11% |
Lombard Odier Asset Management (Switzerland) SA | 996,116 | $14,862,000 | 0.95% |
Coastal Bridge Advisors, LLC | 301,929 | $4,505,000 | 0.94% |
HARBOR CAPITAL ADVISORS, INC. | 119,547 | $1,784,000 | 0.65% |
Pier Capital, LLC | 294,968 | $4,401,000 | 0.46% |
Navalign, LLC | 64,428 | $961,000 | 0.38% |
Gratus Capital, LLC | 191,871 | $2,863,000 | 0.26% |